{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012595","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.517377+00:00","generated_at":"2026-06-24T17:32:35.697667+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kezar Life Sciences estimates $307M cash, cash equivalents and marketable securities as of June 30, 2022","bullets":["Preliminary cash, cash equivalents and marketable securities balance of approximately $307 million as of June 30, 2022.","Estimate is unaudited and subject to quarter-end closing adjustments.","No other financial results for Q2 2022 provided; comprehensive statement not yet available.","Company emphasizes this is a preliminary estimate and not a complete financial report."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012595","json":"https://secwatch.observer/filing/0000950170-22-012595.json","markdown":"https://secwatch.observer/filing/0000950170-22-012595.md","text":"https://secwatch.observer/filing/0000950170-22-012595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/0000950170-22-012595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/kzr-20220711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:32:35.697667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}